|
 Axura
 Merz - our research for your health. In the case of learning and memory processes, the transient synaptic release of glutamate causes more calcium to flow into the cell.
Axura: learn more about the different forms of diseases, current research, drugs, treatment, therapies and care. Axura is a topic that anyone of us should think about, because when growing old, everyone could be affected. Inform yourself about Axura now! The care for elderly people and their diseases are a topic for our society, whose importance grows each day. That's why we at Merz take Axura very serious, so that we can offer you the best drug for each treatment and therapy you need. Axura and Merz means research for your health. High-quality products and information about Axura can be found on our website. Visit us online and learn everything about Axura from one of Germany's leading health care companies. Our contribution to Axura: read here what we can do for you. Further links: Axura: Information for professionals.>>
Axura: learn more about the different forms of diseases, current research, drugs, treatment, therapies and care.
Memantine , Alzheimer's Treatment . Such excitotoxicity ultimately leads to neuronal calcium overload and has been implicated in neurodegenerative disorders. Calcium enters into the cell, and through secondary processes, the signal is recognized. Such excitotoxicity ultimately leads to neuronal calcium overload and has been implicated in neurodegenerative disorders. Senile Dementia , Dementia Care . As memantine, in contrast to magnesium, blocks the NMDA receptor in the presence of sustained release of low glutamate concentrations, the influx of calcium is prevented (neuroprotection). A signal is produced which due to the lower noise can be recognized and processed which leads to a symptomatic improvement in dementia symptoms. The starting point is the pathological release of glutamate, followed by elevated calcium concentrations. Alzheimer's Research , Alzheimer . As memantine, in contrast to magnesium, blocks the NMDA receptor in the presence of sustained release of low glutamate concentrations, the influx of calcium is prevented (neuroprotection). At the same time, Memantine reduces caregiver time by more than 50 hours a month. A signal is produced which due to the lower noise can be recognized and processed which leads to a symptomatic improvement in dementia symptoms. Demenzkranke , Verwirrtheit Gedächtnisstörungen Short Term Memory Loss Symptoms Of Alzheimer's Disease . As memantine, in contrast to magnesium, blocks the NMDA receptor in the presence of sustained release of low glutamate concentrations, the influx of calcium is prevented (neuroprotection). Alzheimer Erkrankung , Symptoms Of Alzheimer's Alzheimer's Disease Symptoms . Glutamate is the principal neurotransmitter in the brain. Memantine produces symptomatic improvements in learning under conditions of tonic NMDA receptor activation in Alzheimer s disease. The excitatory neurotransmitter glutamate plays an important part in the development of neurodegenerative diseases like dementia. Memantine improves cognitive and psychomotor functioning, activities in daily living and the clinical global impression. Glutamate is the principal neurotransmitter in the brain. In studies of memantine, doctors assessed tolerability as good or very good in 93 percent of patients. Alzheimer's Drug Dementia Symptoms , Hirnleistungsstörungen . Therefore memantine has a low potential for day-day interactions in these multimorbid patients. Memantine has been developed as a monotherapeutic. Memantine is a NMDA receptor antagonist and protects the glutamatergic system from pathological activation. Clinically-relevant doses of memantine produce improvements in learning under conditions of tonic NMDA receptor activation in Alzheimer's disease. Merz Pharmaceuticals, as a member of Merz Pharma, is an innovative and international healthcare company, specializing in the research, development and marketing of pharmaceuticals for the treatment of neurological and psychiatric diseases. Demenz Krankheit Alzheimer Behandlung NMDA-Schutz Demenz Früherkennung , Mild Cognitive Impairment Altersdemenz . Therefore memantine has a low potential for day-day interactions in these multimorbid patients. In studies of memantine, doctors assessed tolerability as good or very good in 93 percent of patients. Memantine is the first representative of a new class of Alzheimer drugs, a moderate affinity NMDA-receptor antagonist. Merz Pharmaceuticals, as a member of Merz Pharma, is an innovative and international healthcare company, specializing in the research, development and marketing of pharmaceuticals for the treatment of neurological and psychiatric diseases. The safety of the combination therapy was investigated in a postmarketing surveillance study. Alzheimer und Demenz , Glutamate Demenz Behandlung Demenz-Erkrankung . At the same time, Memantine reduces caregiver time by more than 50 hours a month. Memantine improves cognitive and psychomotor functioning, activities in daily living and the clinical global impression. Alzheimer's Disease Alzheimer Therapie , Symptoms Of Dementia . Memantine is the first representative of a new class of Alzheimer drugs, a moderate affinity NMDA-receptor antagonist. NMDA-Antagonist Forgetfulness , Glutamat Alzheimer Früherkennung . The excitatory effect of chronically released glutamate effects the degeneration of cortical and subcortical neurons, thus leading to the occurrence of dementia symptoms. vaskuläre Demenz , Lewy Body Dementia Demenz Therapie Vascular Dementia . Gedächtnis , Demenz . Merz , Multi Infarct Dementia . Alzheimer's Dementia Axura , Vergesslichkeit Antidementiva Alzheimer's Caregiver . Stages Of Alzheimer's Disease , Akatinol Alzheimer's Support Hirnleistungsstörung NMDA-Protection . Glutamate stimulates a number of postsynaptic receptors, including the N-methyl-D-aspartate (NMDA) receptor, which has been particularly implicated in memory processes, dementia, and the pathogenesis of Alzheimer's disease. Due to its strong voltage-dependency, magnesium leaves the NMDA receptor. Alzheimer's , Demenzerkrankung Dementia . Glutamate stimulates a number of postsynaptic receptors, including the N-methyl-D-aspartate (NMDA) receptor, which has been particularly implicated in memory processes, dementia, and the pathogenesis of Alzheimer's disease. Memory Loss Pseudodemenz Alzheimer's Care , Dementia Treatment . Memantine is the first representative of a new class of Alzheimer drugs, a moderate affinity NMDA-receptor antagonist. Dementia And Alzheimer's Alzheimer Krankheit , Demenzkrank . Alzheimer's Symptoms , Mental Confusion . At the same time, Memantine reduces caregiver time by more than 50 hours a month. Merz is a leader in the field of Alzheimer research and developed the first drug for the treatment of moderate to severe Alzheimer s. Memantine improves cognitive and psychomotor functioning, activities in daily living and the clinical global impression. Glutamate is the principal neurotransmitter in the brain. Dementia Medication Literatur , Erkennung Diagnose Studien . Memantine is the first representative of a new class of Alzheimer drugs, a moderate affinity NMDA-receptor antagonist. The excitatory neurotransmitter glutamate plays an important part in the development of neurodegenerative diseases like dementia. Memantine is well tolerated even in long-term therapy. Memantine is well tolerated even in long-term therapy. Medikamentkombinationen , Demenz Medikament . Therapy , Help . Diagnosis , Information Literature . The excitatory neurotransmitter glutamate plays an important part in the development of neurodegenerative diseases like dementia. Studies , Combination . Treatment Alzheimer's Therapie Demenz Alzheimer Medikament , Medication Alzheimer's .
 Axura
|
